Teleflex reported third quarter 2026 sales of US$567.78 million and net income of US$927.43 million, raised full year GAAP EPS guidance, continued a sizeable buyback program, and affirmed a US$0.34 quarterly dividend payable on December 31, 2026. Management plans to keep directing excess cash toward share repurchases and potential tuck in acquisitions that align with its three core businesses, pairing this with R&D and CapEx investment to support the current transformation program. The next...
Teleflex (TFX) just paired fresh third quarter 2026 results with a clear capital play, combining higher earnings guidance, ongoing share repurchases, and a newly affirmed quarterly dividend. The fresh guidance, active buyback and affirmed dividend have landed alongside a sharp shift in how the market is pricing Teleflex. The stock’s share price has climbed 21.20% over the past 30 days and 23.26% year to date, while total shareholder return sits at 39.44% over the last 12 months but remains...
While the top- and bottom-line numbers for Teleflex (TFX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Teleflex reported that the U.S. FDA granted Breakthrough Device Designation to its Freesolve Resorbable Magnesium Scaffold for PCI, recognizing its potential to address unmet clinical needs in treating serious coronary disease. The device’s resorbable magnesium platform, supported by BIOMAG clinical data and existing CE Mark availability outside the U.S., indicates a meaningful R&D asset within Teleflex’s Interventional pipeline. This raises the question of how Teleflex’s investment...
WAYNE, Pa., October 22, 2026--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 5, 2026.
Teleflex (NYSE:TFX) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs.
TFX's Vascular growth, Asia expansion and improved leverage support the outlook, but tariffs, input costs and margin pressure remain key risks.
Tipranks Press Release.
Detailed price information for Nyxoah S A (NYXH-Q) from The Globe and Mail including charting and trades.
Detailed price information for Nvidia Corp (NVDA-Q) from The Globe and Mail including charting and trades.
WAYNE, Pa., September 29, 2026--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters (CVCs) protected with Arrowg+ard™ Technology were associated with a statistically significant 70% lower hazard of central line-associated bloodstream infections (CLABSIs) compared with plain, non-impregnated catheters during a
Shares of medical technology company Teleflex (NYSE:TFX) jumped 4.5% in the afternoon session after BofA Securities upgraded the stock from Neutral to Buy and raised its price target.
(Updated to include previous price target in headline.) Teleflex (TFX) has an average rating of o
This is the newest page. Registered accounts read further back.